What is the brand name of margetuximab in China?

Margetuximab (margetuximab-cmkb), as an innovative monoclonal antibody targeting the HER2 receptor, has gradually gained widespread attention around the world in recent years, especially in the treatment of HER2-positive breast cancer and other solid tumors, showing positive clinical effects. With the introduction of this drug in China, more and more patients and doctors are paying attention to its accessibility and related information in the domestic market.

Currently, the trade name of margetuximab in China is "MARGENZA", a name that has gradually established recognition in the domestic pharmaceutical market. As an original biological agent, Meganle uses advanced Fc engineering technology to enhance the immune system's recognition and killing of tumor cells and improve the therapeutic effect. The drug enhances antibody-dependent cellular cytotoxicity (ADCC) by optimizing the binding of the Fc segment to Fcγ receptors on immune cells (especially the activating receptor FcγRIIIa/CD16A), helping to activate natural killer cells and macrophages, thereby achieving a more effective anti-tumor effect.

Marginal's clinical data shows that in patients with HER2-positive advanced breast cancer, especially those who are resistant to standard treatments such as trastuzumab, magituximab can provide an effective treatment option and extend progression-free survival and overall survival.

Although Meganle has been launched in China, due to its short market time, the current specific pricing has not yet been fully disclosed, and it has not been included in the national medical insurance directory. This results in patients who may face higher drug cost pressure when purchasing. Therefore, when patients are preparing to use margituximab for treatment, it is recommended that they first consult the attending doctor, the pharmacy of the hospital or a professional medical institution for the latest drug supply and price information in order to make a treatment budget and plan arrangement.

Reference materials:https://www.margenza.com/